Clinical trial
A Randomized, Open-Label, Treat-to-Target, Parallel-Controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of Fixed-Dose Titration and Individualized-Dose Titration of SHR-3167 in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents
NCT07472725 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-Label, Treat-to-Target, Parallel-Controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of Fixed-Dose Titration and Individualized-Dose Titration of SHR-3167 in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 11, 2026
- Completion date
- February 28, 2027
- Enrollment
- 102 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.